Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Premaitha - good Leads from Leeds, buy

By HotStockRockets

4 February 2016 02:15

More:

Premaitha Health (NIPT) has announced a partnering with Leeds Teaching Hospitals NHS Trust - one of the largest in England - to provide a private non-invasive prenatal screening service for pregnant women in the region.

Already a member? Sign in

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 13 year archive

• ShareProphets Daily Newsletter

Cancel any time

This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

Comments

wildrides

4 February 2016, 03:17

Sell ………….and buy it back cheap near the court case date . Next you will be telling us they have a test kit outlet in India where the illumina patents dont reach . Trouble is there are only four people in India that can afford it ………and they are all men .
Alquemie

4 February 2016, 04:31

There are a number of Indian pathology labs offering non-invasive prenatal testing and at least two tests launched by Indian companies. There are no national guidelines and marketing is largely unregulated. The cost of testing has come down but is still around the £300 mark. NIPT is now available in most countries (it was commercially available in Hong Kong before even before the US).
uriah heep

4 February 2016, 05:36

In my humble opinion the company is issuing too many wishy-washy RNSs.
Sachin Melwani

10 February 2016, 08:58

Tom,
Can you please expand on your last statement…
“We expect further contract wins to come shortly which will underpin our belief that the company is already approaching breakeven and will move into material profit in the year to March 2017”.

Are you saying you have been told there will be further contract winds after the contract in India before the Financial Year End in March ’16? It seems strange that you are saying that Premaitha will be cash positive in March ’17 when Hardman said March ’19. This is a stonking big ramp if not genuine. Who is your source on this and can you please share your break even point and forecasts?